ProCE Banner Activity

CME

On-Demand Webcast: Clinical Insights on Expanding Systemic Treatment Options in HCC

Multimedia
In this on-demand Webcast of the live symposium in Chicago, our distinguished faculty provide insight into the key emerging and practice-changing approaches to systemic therapy in advanced HCC.

Physicians : maximum of 1.25 AMA PRA Category 1 {Credits}

Released: July 11, 2017

Expiration: July 10, 2018

No longer available for credit.

Share

Faculty

Tanios Bekaii-Saab

Tanios Bekaii-Saab, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Leader
Gastrointestinal Cancer Program
Mayo Clinic Cancer Center
Phoenix, Arizona

Peter R. Galle

Peter R. Galle, MD, PhD

Chairman
First Department of Internal Medicine
University Medical Center
Mainz, Germany

Tim F. Greten

Tim F. Greten, MD

National Cancer Institute
Bethesda, Maryland
Former Associate Professor of Medicine
Department of Gastroenterology and Hepatology
Hannover Medical School
Hannover, Germany

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Eisai

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with hepatocellular carcinoma

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Gain insight on therapeutic strategies to maximize the efficacy of sorafenib in advanced HCC
  • Evaluate the therapeutic impact of regorafenib in patients with HCC and disease progression after first-line treatment with sorafenib
  • Consider the biologic rationale and the efficacy and safety evidence for molecularly targeted agents in advanced HCC
  • Incorporate novel agents and clinical trial participation as part of clinical care strategies for HCC
  • Differentiate the mechanisms of action and scientific rationale for the use of immunotherapy approaches in HCC
  • Evaluate the efficacy and safety data on immune checkpoint inhibitors for the treatment of HCC

Program Director Disclosure

Program Director

Tanios Bekaii-Saab, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Leader
Gastrointestinal Cancer Program
Mayo Clinic Cancer Center
Phoenix, Arizona

Tanios Bekaii-Saab, MD, FACP, has disclosed that he has received consulting fees from Bayer, Boehringer Ingelheim, Celgene, Coherus, Glenmark, Merrimack, and Taiho.

Faculty Disclosure

Primary Author

Peter R. Galle, MD, PhD

Chairman
First Department of Internal Medicine
University Medical Center
Mainz, Germany

Peter R. Galle, MD, PhD, has disclosed that he has received consulting fees and fees for non-CME services from AstraZeneca, Bayer, Bristol-Myers Squibb, Lilly, MSD, Sillajen, and Sirtex.

Tim F. Greten, MD

National Cancer Institute
Bethesda, Maryland
Former Associate Professor of Medicine
Department of Gastroenterology and Hepatology
Hannover Medical School
Hannover, Germany

Tim F. Greten, MD, has no real or apparent conflicts of interest to report.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no real or apparent conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 11, 2017, through July 10, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ competence in and performance at applying evidence-based systemic therapy approaches to optimize clinical outcomes for patients with metastatic hepatocellular carcinoma.